Treatment for RA at final visit† or AE onset‡
| Total N=51 | Non-AE group§ N=40 (78%) | AE group¶ N=11 (22%) | p Value | |
|---|---|---|---|---|
| Treatment, yes | 37 (73) | 27(68) | 10 (91) | 0.12 |
| Corticosteroid | 29 (57) | 22 (55) | 7 (64) | 0.61 |
| Immunosuppressant except for MTX | 17 (33) | 14 (35) | 3 (27) | 0.63 |
| MTX | 10 (20) | 4 (10) | 6 (55) | 0.001* |
| Other drugs | 17 (33) | 13 (33) | 4 (36) | 0.81 |
Data are presented as n (%) and compared between non-AE group and AE group using Fisher's exact test.
Immunosuppressant except for MTX included azathioprine (n=1), cycrophosphaminde (n=1), etanercept (n=2), mizoribine (n=7) and tacrolimus (n=6).
Other drugs included actarit (n=2), bucillamine (n=5), meloxicam (n=1) and salazosulfapyridine (n=11).
*p<0.05.
†In non-AE group.
‡In AE group.
§Non-AE group, patients who did not develop AE during the observation period.
¶AE group, patients who developed AE during observation period.
AE, acute exacerbation; ILD, interstitial lung disease; MTX, methotrexate; RA, rheumatoid arthritis.